JAK Inhibitors in RA: Applying Evidence-Based Strategies in Clinical Decision-making

Hear from the experts as they highlight the latest clinical trial and real-world evidence regarding JAK inhibitor efficacy and safety to help contextualize risks and apply practical mitigation strategies to comprehensive care plans.
Vivian P. Bykerk, MD, FRCPC
person default
Vibeke Strand, MD, MACR, FACP
Format: Microsoft PowerPoint (.ppt)
File Size: 510 KB
Released: November 14, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an educational grant from
Lilly

Related Content

Stanley B. Cohen, MD, answers questions about the ACR 2020 Pharmacologic Recommendations for the management of RA.

Stanley B. Cohen, MD Released: December 23, 2020

Maria Danila, MD, MSc, MSPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: No longer available for credit

From ACR/ARP 2020: expert-authored commentary on tapering RA therapy, as reported by Clinical Care Options (CCO)

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: No longer available for credit

From ACR/ARP 2020: expert-authored commentary on evaluating RA and the utility of telemedicine, as reported by Clinical Care Options (CCO)

Jonathan Kay, MD William F. C. Rigby, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: No longer available for credit

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings